Ovarian Cancer Clinical Trial
Natera Ovarian Cancer Detection Assay
Summary
The purpose of this study is to enroll participants who present with an adnexal mass on imaging to develop a non-invasive ovarian cancer assay to distinguish between malignant and benign masses. The study will collect blood, tissue, and health information from these individuals.
Eligibility Criteria
Inclusion Criteria:
Presenting to clinic with adnexal mass suspicious of ovarian, fallopian tube, or peritoneal cancer on imaging
Must be planning surgical resection or biopsy
Must be treatment naïve
Must be 18 years or older
Able to understand and sign a written informed consent document
Able to provide 40mL of blood (at least 20mL) for each blood draw
Exclusion Criteria:
Prior removal of either ovary for any reason
Currently pregnant
Blood transfusion within 3 months of study enrollment
History of bone marrow or organ transplant
Prior history and treatment for any malignancy, with exception of previously treated non-melanoma skin cancer.
A medical condition that would place subject at risk as a result of the blood donation, including but not limited to bleeding disorders, chronic infectious disease, emphysema or serious anemia
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Pittsburgh Pennsylvania, 15213, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.